”Here are three key things you need to know: • We have promising technologies that are already in human trials, or about to go into trials – this is critical, since in biotech the “rubber hits the road” once you are in humans with your drug; • The leadership team under our CEO Jenn Chow, is first class, and we have selectively built out a management team of cell therapy specialists to expertly guide the development of our drugs; • We have cash in the bank following our Rights Issue early this year, and more recently we provided a further buffer against the capital markets, by entering into a funding proposal with L1 Capital.
As a Company, we remain focusedon staying the course, there is a high degree of enthusiasm among us and an optimism that we have the right assets and the right people to take us forward.At some point this will be recognised by the market.
P A U L H O P P E R C H A I R M A N A N D F O U N D E R
CHM Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)